Date
- 2026 (30)
- 2025 (23)
- 2024 (40)
- 2023 (48)
- 2022 (26)
- 2021 (101)
- 2020 (61)
- 2019 (126)
- 2018 (40)
- 2017 (21)
- 2016 (22)
- 2015 (14)
- 2014 (22)
- 2013 (7)
- 2012 (3)
- 2010 (2)
- 2009 (10)
- 2008 (5)
- 2007 (11)
- 2006 (10)
- 2005 (12)
- 2004 (4)
- 2003 (2)
- 2002 (6)
- 2001 (3)
- 2000 (11)
- 1999 (5)
- 1998 (3)
- 1997 (1)
- 1996 (7)
- 1995 (2)
- 1994 (6)
- 1993 (5)
- 1991 (17)
Sponsor content
706 result(s) found, displaying 11 to 20
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ALTUVIIIO efanesoctocog alfa 250 IU powder for injection vial.
-
Australian Public Assessment Report (AusPAR)Tzield is indicated to delay the onset of Stage 3 type 1 diabetes mellitus (T1D) in adult and paediatric patients aged 8 years and older with Stage 2 type 1 diabetes mellitus.
-
Prescription medicine decision summaryALTUVIIIO (efanesoctocog alfa) is approved for adults, adolescents and children with haemophilia A.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for TZIELD teplizumab 2 mg/2 mL Concentrated injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CENRIFKI tolebrutinib 60mg film coated tablet blister pack.
-
Prescription medicine registrationActive ingredients: efanesoctocog alfa.
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Prescription medicine decision summaryTzield (teplizumab) is approved to delay the onset of Stage 3 type 1 diabetes mellitus (T1D) in adult and paediatric patients aged 8 years and older with Stage 2 type 1 diabetes mellitus.
-
Prescription medicine decision summaryCenrifki (tolebrutinib) has been approved for the treatment of Secondary Progressive Multiple Sclerosis (SPMS) in adults.
-
Jun-2026Prescription medicine evaluationActive ingredient: Influenza virus haemagglutinin.